BioCentury | Sep 10, 2020
Product Development

BioNTech, Pfizer complete exploratory talks with the European Commission for 200M COVID-19 vaccine doses

...for Phase II/II testingAmpio Pharmaceuticals Inc. (NYSE-A:AMPE) said Ampion...
...Phase II/III trial.TARGETSACE2 – Angiotensin-converting enzyme 2 Sandi Wong BNT162b2 Ampion...
BioCentury | Mar 25, 2020
Product Development

COVID-19 roundup: Emergency use of Moderna vaccine could come earlier than expected; plus ASCO goes virtual, Galapagos pauses filgotinib trials and more

...stopped enrolling patients with severe osteoarthritis of the knee in a Phase III trial of Ampion...
BioCentury | Aug 10, 2018
Clinical News

FDA requests additional trial for Ampio's osteoarthritis therapy Ampion

...Ampio Pharmaceuticals Inc. (NYSE-M:AMPE) said FDA requested an additional randomized trial of Ampion to treat severe...
...a BLA submission. Ampio had positioned AP-003-C as the second. In December, Ampio reported that Ampion...
...cleaved from human serum albumin. Ampio Pharmaceuticals Inc. (NYSE-M:AMPE), Englewood, Colo. Product: Ampion Business: Autoimmune Mary Romeo Ampion Ampio...
BioCentury | Jan 9, 2018
Finance

Stars in China

...Pharmaceuticals Inc. was among the leading performers. The biotech’s shares rose 566% after reporting that Ampion...
...primary endpoint in the Phase III AP-003-C trial to treat severe osteoarthritis of the knee. Ampion...
...“Burgeoning bellwethers.” BioCentury (2018) Cukier-Meisner, E. “Car dealing.” BioCentury (2018) Amran Gowani, Senior Editor, Research & Analytics Ampion ANB020 cabiralizumab CART-BCMA laquinimod LCAR-B38M Mongersen Opdivo PARP...
BioCentury | Jan 6, 2018
Finance

Burgeoning bellwethers

...ethyl Reduce major adverse cardiovascular events (MACE) Ph III data 2018 Ampio Pharmaceuticals Inc. (NYSE-M:AMPE) Ampion...
BioCentury | Dec 15, 2017
Clinical News

Ampio's Ampion meets in latest Phase III OA trial

...Ampio Pharmaceuticals Inc. (NYSE-M:AMPE) said Ampion met the primary endpoint in the Phase III AP-003-C trial...
...a BLA for Ampion to treat signs and symptoms of severe OA of the knee. Ampion...
...April 27, 2015 & July 11, 2016 ). Among AP-003-C's 144 patients who received Ampion...
BioCentury | Dec 14, 2017
Clinical News

Latest Phase III OA readout boosts Ampio shares

...Ampio Pharmaceuticals Inc. (NYSE-M:AMPE) added $0.58 (33%) to $2.33 on Thursday after reporting that Ampion met...
...a BLA for Ampion to treat signs and symptoms of severe OA of the knee. Ampion...
...not used for analysis. Ampion is a cyclic aspartate-alanine dipeptide cleaved from human serum albumin. Chris Lieu Ampion Ampio...
BioCentury | May 17, 2017
Clinical News

Ampio starts pivotal trial of Ampion for OA of the knee

...Ampio Pharmaceuticals Inc. (NYSE-M:AMPE) began a blinded, placebo-controlled, pivotal trial evaluating single intra-articular injections of Ampion...
...by Osteoarthritis Research Society International (OARSI) score in about 171 patients. Ampio said only the Ampion-treated...
...be evaluated. The company said it will "advance necessary BLA activities" concurrently with the trial. Ampion...
BioCentury | Dec 2, 2016
Clinical News

Ampion: Preliminary Ph I data

...trial in 15 patients showed that a single intra-articular injection of up to 3 mL Ampion...
...to evaluate efficacy, reductions in pain were reported in 6 of 9 patients treated with Ampion...
...saline control. Ampio said it expects a final FDA decision on its BLA submission for Ampion...
BioCentury | Jul 11, 2016
Clinical News

Ampion: Phase III data

...due to OA of the knee showed that a single 4 mL intra-articular injection of Ampion...
...improving WOMAC-A pain subscale score from baseline to week 12 vs. saline. Compared to baseline, Ampion...
...of Ampion in the most severe OA patients. Ampio Pharmaceuticals Inc. (NYSE-M:AMPE), Englewood, Colo. Product: Ampion...
Items per page:
1 - 10 of 53